Join the Ticagrelor group to help and get support from people like you.
Ticagrelor News
ACC: Ticagrelor Monotherapy Cuts Bleeding Risk in Acute Coronary Syndrome
MONDAY, April 8, 2024 – Treatment with ticagrelor alone results in a lower rate of clinically relevant bleeding compared with ticagrelor and aspirin among patients with an acute coronary syndrome...
TCT: Ticagrelor Monotherapy Within One Month of DAPT Noninferior to Continued DAPT
FRIDAY, Oct. 27, 2023 – For patients with acute coronary syndrome (ACS), stopping dual antiplatelet therapy (DAPT) within one month for ticagrelor monotherapy is noninferior and superior to 12...
P2Y₁₂ Inhibitor Monotherapy Better Than Aspirin in Coronary Artery Disease
MONDAY, July 10, 2023 – For patients with coronary artery disease (CAD), P2Y12 inhibitor monotherapy is associated with a lower risk for cardiovascular death, myocardial infarction, and stroke...
Ticagrelor-Acetylsalicylic Acid More Beneficial for Obese With Minor Stroke, TIA
MONDAY, July 10, 2023 – For patients with minor stroke or transient ischemic attack (TIA) who carry the CYP2C19 loss-of-function allele, those with obesity receive more clinical benefit from...
Brilinta Approved in the US to Reduce the Risk of Stroke in Patients with an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack
6 November 2020 – AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of stroke, a leading cause of disability and death worldwide, in patients with acute ischemic str...
Brilinta Approved in the US to Reduce the Risk of a First Heart Attack or Stroke in High-Risk Patients with Coronary Artery Disease
June 1, 2020 – AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease (CAD), the most ...
FDA Medwatch Alert: Brilinta (ticagrelor) 90 mg tablets, 8-count Physician Sample Bottles: Recall of Lot # JB5047 - Due to Report of Another Medicine in One Bottle
ISSUE: AstraZeneca is notifying physicians and consumers that it is voluntarily recalling one lot of professional (physician) sample bottles containing eight tablets of Brilinta (ticagrelor) 90mg...
Brintellix (vortioxetine) Renamed Trintellix (vortioxetine) in U.S. to Avoid Name Confusion
Deerfield, Ill., and Osaka, Japan (May 2, 2016) – Takeda Pharmaceuticals U.S.A., Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502) (collectively “Takeda”), and Lundb...
FDA Medwatch Alert: Brintellix (vortioxetine): Drug Safety Communication - Brand Name Change to Trintellix, to Avoid Confusion With Antiplatelet Drug Brilinta (ticagrelor)
ISSUE: FDA has approved a brand name change for the antidepressant Brintellix (vortioxetine) to decrease the risk of prescribing and dispensing errors resulting from name confusion with the ...
FDA Approves Expanded Indication for Brilinta to Include Long-Term Use in Patients with a History of Heart Attack
Thursday, 3 September 2015 – AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Brilinta (ticagrelor) tablets at a new 60mg dose to be used in patients with a...
FDA Medwatch Alert: Brintellix (vortioxetine) and Brilinta (ticagrelor): Drug Safety Communication - Name Confusion
ISSUE: FDA is warning health care professionals and patients that reports of confusion between the antidepressant Brintellix and anti-blood clotting medication Brilinta have resulted in the wrong...
FDA Approves New Crushing Option for the Administration of Brilinta
March 30, 2015 – AstraZeneca (NYSE: AZN) today announced that the US Food and Drug Administration (FDA) has approved a new administration option for acute coronary syndrome (ACS) patients who are...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Coronary Artery Disease (CAD), Myocardial Infarction, Heart Attack, Cardiovascular Risk Reduction, Thromboembolic Stroke Prophylaxis